课件：乳腺癌的内分泌治疗演示课件.pptVIP

Protocol 025 Study Design:Letrozole vs. Tamoxifen as First-Line Therapy Survival follow-up Study population: Postmenopausal; locally advanced or locoregionally recurrent or metastatic breast cancer; ER and/or PgR positive or unknown Letrozole 2.5 mg od Tamoxifen 20 mg od Letrozole 2.5 mg od Tamoxifen 20 mg od Optional Crossover Progression Progression Mouridsen et al. J Clin Oncol. 2001;19: 2596. Core PhaseDouble-Blind (randomized) Extension Phase Double-Blind (not randomized) 3.5 y 1.5 y Letrozolen=453 Tamoxifenn=454 P Value Hazard Ratio (95% CI) Progression 79% 85% 0.72 TTP (medi